Abstract-The renin-angiotensin system is a major physiological regulator of body fluid volume, electrolyte balance, and arterial pressure. Virtually all of the biological actions of the principle effector peptide angiotensin II (ANG II) have been attributed to an action at the type 1 (AT 1 ) ANG receptor. Until recently, the functional role of the type 2 (AT 2 ) receptor, if any, has been unknown, possibly because the AT 2 receptor has a low degree of expression compared with that of the AT 1 receptor. Evidence has now accumulated that the AT 2 receptor opposes functions mediated by the AT 1 receptor. Whereas the AT 1 receptor stimulates cell proliferation, the AT 2 receptor inhibits proliferation and promotes cell differentiation. These differences in growth responses have been ascribed to different cell signaling pathways in which the AT 1 receptor stimulates protein phosphorylation and the AT 2 receptor dephosphorylation. During the past 5 years, studies have demonstrated that the AT 2 receptor is responsible for vasodilation and natriuresis, thus opposing the vasoconstrictor and antinatriuretic effects of ANG II mediated through the AT 1 receptor. Work from our laboratory and others indicates that the AT 2 receptor stimulates vasodilation and natriuresis by an autocrine cascade including bradykinin, nitric oxide, and cyclic GMP. The AT 2 receptor also has been found to control vasodilator prostaglandins, which have a role in blood pressure regulation. The AT 2 receptor appears to play a counterregulatory protective role in the regulation of blood pressure and sodium excretion that opposes the AT 1 receptor. Key Words: angiotensin II Ⅲ receptors, angiotensin II Ⅲ blood pressure Ⅲ kidney Ⅲ sodium T he renin-angiotensin system is a major physiological regulator of body fluid volume, electrolyte balance, and blood pressure. 1-4 However, the mechanisms by which these actions occur remain incompletely understood. The biological actions of angiotensin II (ANG II), the system's major effector peptide, have been studied for decades and were thought to be mediated by a single ANG II receptor. [1] [2] [3] [4] In the late 1980s, however, the development of highly specific nonpeptide antagonists of the ANG II receptor (s) opened the door to the identification and pharmacological characterization of 2 major receptor subtypes, AT 1 and AT 2 . 1-6 AT 1 receptors were defined as those selectively blocked by biphenylimidazoles such as losartan, whereas AT 2 receptors were defined as those blocked by tetrahydroimidazopyridines, typified by PD 123319 (PD). 5, 6 In the first half of the 1990s, virtually all of the biological actions of ANG II were characterized by these prototype receptor antagonists as acting through the AT 1 receptor, and the functions of the AT 2 receptor were unknown. [1] [2] [3] [4] More recently, each of these receptors has been cloned and the signal transduction mechanisms for the AT 1 and AT 2 receptors have been clarified. [1] [2] [3] [4] 7, 8 We now have available a great deal of information concerning the receptor genes, molecular and protein structures, sites and regulation of expression, and cellular mechanisms of action. This review will focus on the AT 2 receptor, the physiological function of which was largely unclear until approximately 4 years ago, when studies began to elucidate novel physiological actions of ANG II at the AT 2 receptor. 9 In this review, we will emphasize the actions of ANG II mediated by the AT 2 receptor that influence blood pressure and renal function. The physiological actions of ANG II at the AT 2 receptor have been difficult to elicit, at least in part because the AT 2 receptor has a low degree of expression in many organs, tissues, and cell types compared with that of AT 1 receptors. 10 -16 However, it is now clear that although the AT 2 receptor is highly expressed in fetal life and declines rapidly after birth, the receptor is expressed in the adult and participates in physiological regulation. 17, 18 The AT 2 receptor also is reexpressed in response to injury.
T he renin-angiotensin system is a major physiological regulator of body fluid volume, electrolyte balance, and blood pressure. [1] [2] [3] [4] However, the mechanisms by which these actions occur remain incompletely understood. The biological actions of angiotensin II (ANG II), the system's major effector peptide, have been studied for decades and were thought to be mediated by a single ANG II receptor. [1] [2] [3] [4] In the late 1980s, however, the development of highly specific nonpeptide antagonists of the ANG II receptor (s) opened the door to the identification and pharmacological characterization of 2 major receptor subtypes, AT 1 and AT 2 . 1-6 AT 1 receptors were defined as those selectively blocked by biphenylimidazoles such as losartan, whereas AT 2 receptors were defined as those blocked by tetrahydroimidazopyridines, typified by PD 123319 (PD). 5, 6 In the first half of the 1990s, virtually all of the biological actions of ANG II were characterized by these prototype receptor antagonists as acting through the AT 1 receptor, and the functions of the AT 2 receptor were unknown. [1] [2] [3] [4] More recently, each of these receptors has been cloned and the signal transduction mechanisms for the AT 1 and AT 2 receptors have been clarified. [1] [2] [3] [4] 7, 8 We now have available a great deal of information concerning the receptor genes, molecular and protein structures, sites and regulation of expression, and cellular mechanisms of action. This review will focus on the AT 2 receptor, the physiological function of which was largely unclear until approximately 4 years ago, when studies began to elucidate novel physiological actions of ANG II at the AT 2 receptor. 9 In this review, we will emphasize the actions of ANG II mediated by the AT 2 receptor that influence blood pressure and renal function. The physiological actions of ANG II at the AT 2 receptor have been difficult to elicit, at least in part because the AT 2 receptor has a low degree of expression in many organs, tissues, and cell types compared with that of AT 1 receptors. 10 -16 However, it is now clear that although the AT 2 receptor is highly expressed in fetal life and declines rapidly after birth, the receptor is expressed in the adult and participates in physiological regulation. 17, 18 The AT 2 receptor also is reexpressed in response to injury.
General Considerations of AT 2 Receptors
The molecular structure of the AT 2 receptor resembles that of the superfamily of G-protein-coupled receptors containing 7 transmembrane regions. 7, 19 The cDNA for the AT 2 receptor encodes a 363-amino acid protein (Figure 1) , with a molecular weight of 41 220 Da. The AT 2 receptor shares only Ϸ34% sequence homology with the AT 1 receptor. 20 The gene for the AT 2 receptor resides on the X-chromosome and has 3 exons with the entire coding region on the third exon. 20 Promoter activity of the rat AT 2 receptor gene is regulated by a number of cis-regulator domains. 20 The AT 2 receptor protein contains 5 potential glycosylation sites in its extracellular N-terminal tail. Among the many differences in amino acid sequence, the AT 2 receptor but not the AT 1 receptor has a conserved LYS 199 , which is important in ligand-receptor interactions. In addition, there is a potential protein kinase-C phosphorylation site in the second intracellular loop and there are 3 consensus sequences for phosphorylation by protein kinase-C and 1 phosphorylation site by cyclic AMP (cAMP)-dependent protein kinase in the C-terminal cytoplasmic tail of the receptor. 2 The signal transduction mechanisms for the AT 2 receptor are still not well defined. The growth-inhibitory effects of the AT 2 receptor are at least partially mediated by the activation of phosphotyrosine phosphatase, resulting in the inactivation of mitogen-activated protein (MAP) kinase, especially p 42 and p 44 MAP kinases, termed extracellular signal-regulated kinases (ERK). 8, [21] [22] [23] [24] With respect to G-protein coupling, the data remain incomplete. Pertussis toxin attenuated AT 2 receptor-mediated inhibition of ERK activity, which suggests that G i is involved in AT 2 receptor cell signaling. 24 In a study of whole rat fetus, antibodies specific for G i␣ coselected AT 2 receptor binding sites in a heterogeneous mixture of cell membranes. 25 Also, transfection of the synthetic third intracellular loop peptide of the AT 2 receptor into rat aortic vascular smooth muscle cells resulted in ERK inactivation, growth inhibition, and immunoprecipitation of the third loop peptide with anti-G i␣ antibody. 22 Evidence for G-protein coupling also has come from studies in neuronal cells demonstrating that the AT 2 receptor activates G i in the modulation of K ϩ channels. 26, 27 AT 2 receptors also activate MAP kinase phosphatase-1 and SHP-1 tyrosine phosphatase, a soluble tyrosine phosphatase. 28 In addition, in the proximal renal tubule, AT 2 receptors appear to be linked to phospholipase A 2 (PLA 2 ). 29 Altogether, the evidence suggests that the AT 2 receptor may be coupled to G-proteins and that the third intracellular loop may be linked with the cell signaling pathway involving G i and ERK inactivation. However, activation of G-proteins in cell membranes by the agonist ANG II has not yet been demonstrated for the AT 2 receptor, and much further work is required to define the cell signaling pathways of the receptor.
AT 2 Receptor Expression and Regulation
The AT 2 receptor is widely expressed in fetal tissues, but in almost all tissues there is rapid regression to low levels or disappearance of expression in the early postnatal period. 10 -18,30 -33 Tissues in which AT 2 receptor expression does not substantially regress and disappear in adulthood include brain, uterine myometrium, and adrenal zona glomerulosa and medulla. During fetal life, the AT 2 receptor gene is expressed predominantly in areas of active mesenchymal differentiation, but the mRNA expression level decreases rapidly and disappears within days after birth. [12] [13] [14] [15] In the adult, AT 2 receptor mRNA has been detected in the adrenal gland, heart, and brain. 12, [33] [34] [35] AT 2 receptor mRNA is expressed in the fetal and neonatal rat kidney but disappears after the neonatal period and is not expressed in the normal adult. 12, 13 The same also appears to be true for heart. 8 Although AT 2 receptor mRNA is not expressed in adult kidney, AT 2 receptor protein has been detected by immunohistochemistry and Western blot analysis with the use of a specific polyclonal antibody to the AT 2 receptor in the rat kidney. 17 Consistent with previous reports of AT 2 receptor mRNA, receptor protein was mainly observed in the mesenchyme of fetal kidney, and receptor protein expression decreased markedly after birth. 17 In the newborn kidney, AT 2 receptor protein was detected in cortical glomeruli and tubule elements as well as in undifferentiated mesenchymal cells. In adult animals, renal AT 2 receptor protein was present predominately in glomeruli but was markedly diminished compared with that of newborn rats. AT 2 receptor protein also was found in small quantities in cortical tubules and interstitial cells in the adult. 17 The AT 2 receptor protein in the adult was upregulated in glomeruli, tubules, and interstitium in response to dietary sodium restriction. The mechanism of reexpression of the AT 2 receptor during sodium restriction is unknown. In humans, the AT 2 receptor protein is expressed in glomerular, tubular, and vascular elements (Figure 2 ), but the regulation of receptor protein expression is unknown.
AT 2 receptor protein also has been detected in the heart by Western blot analysis and immunocytochemistry. 18 AT 2 receptor protein was present both in myocardium and coronary vessels throughout the ventricle and atrium of neonatal and young adult rat hearts. 18 AT 2 receptor protein was present only in the endothelium and not in smooth muscle cells of coronary arteries. 18 By Western blot analysis, neonatal rat heart expressed significantly more AT 2 receptors than young adult hearts.
Several factors regulate the expression of the AT 2 receptor. 17,36 -44 ANG II, norepinephrine, insulin-like growth factor, basic fibroblast growth factor, and transforming growth factor-␤ all decrease AT 2 receptor expression. 17, 36, 37 AT 2 receptor expression is increased in experimental heart failure, myocardial infarction, vascular injury, and dietary sodium has not yet been crystallized, so the actual tertiary structure is unavailable. The figure depicts the 7-transmembrane spanning regions, extracellular and intracellular domains, and the 17-amino acid sequence in the extracellular N-terminal tail, to which the polyclonal antibody described in References 17 and 18 was generated (yellow circle).
restriction. 38 -40 The reason for the discrepancy between the effects of ANG II and sodium restriction are unclear.
Taken altogether, the available evidence suggests that although AT 2 receptor mRNA is not expressed in detectable quantities in the adult kidney, heart, and vasculature, the receptor protein is present in a site-specific distribution and may be regulated by physiological maneuvers such as sodium depletion.
General Functions of the AT 2 Receptor
The AT 2 receptor has several newly described functions related to cell growth, differentiation, and ultimate fate. In general, the AT 2 receptor inhibits cell growth and proliferation and promotes cell differentiation, counterbalancing the opposite effects of ANG II at the AT 1 receptor. [45] [46] [47] [48] Antiproliferative effects on ANG II by the AT 2 receptor have been identified in several different cell types including endothelial cells, neonatal cardiomyocytes, cardiac fibroblasts, and vascular smooth muscle cells. Recent studies also suggest that the AT 2 receptor inhibits angiogenesis. 3 Although there is substantial evidence that the AT 2 receptor mediates apoptosis, the findings remain somewhat controversial. [1] [2] [3] The AT 2 receptor has distinctive physiological actions in neuronal cells. AT 2 receptors inhibit low-voltage T-type calcium channels in undifferentiated neuronal cells, which express only the AT 2 subtype of angiotensin receptors. 49, 50 This biological action is of short duration and therefore it is possible that AT 2 receptors could regulate the pacemaker activity of neuronal cells. In neuronal cells from neonatal animals, AT 2 receptors activate the delayed rectifier K ϩ channel leading to increased cellular polarization. 26 In catecholaminergic neurons, the AT 2 receptor increases delayed K ϩ rectifier current and inhibits norepinephrine release initiated by the AT 1 receptor. 3 In peripheral neurons, the AT 2 receptor increases a neurite-promoting protease, Nexin-1, in Schwann cells. AT 2 receptor stimulation also promotes neuronal differentiation, including neurite outgrowth and upregulation of polymerized tubulin. These effects promote neuronal regeneration through the AT 2 receptor. [51] [52] [53] The AT 2 receptor stimulates jejunal sodium and water absorption by a pathway that includes stimulation of the sympathetic nervous system and nitric oxide (NO) production. 54 The final effector of this pathway is cyclic GMP (cGMP), which is released into the interstitial fluid on the serosal side of the transporting epithelial cells. 55 This pathway opposes the actions of ANG II by the AT 1 receptor to inhibit sodium and water absorption through a prostaglandin E 2 -dependent and cAMP-dependent mechanism. 54 
Role of the AT 2 Receptor in Renal Function
The renin-angiotensin system plays a major role in the physiological regulation of the kidney, including the control of renal microvascular and tubular function. Before 1996, virtually all studies indicated that the renal actions of ANG II are mediated by the AT 1 receptor. 9, 56 As discussed earlier, AT 2 receptors are expressed to a low degree in the kidney compared with AT 1 receptors. The predominance of renal AT 1 over AT 2 receptor expression in all likelihood explains past difficulty in eliciting AT 2 receptor-related actions. 17, 44 Well-known renal actions of ANG II mediated by the AT 1 receptor include increased tubular sodium absorption at low doses, inhibition of reabsorption at higher doses, afferent and efferent arteriolar vasoconstriction, and glomerular mesangial cell contraction and constriction of renal vessels, including the arcuate and interlobular arteries and vasa recta. 56, 57 These actions produce integrated physiological actions including decreased renal blood flow, glomerular filtration rate, and sodium excretion.
In addition to direct effects of ANG II on vascular smooth muscle and tubule cells, the peptide can stimulate the release of vasoactive factors from endothelial, vascular smooth muscle, mesangial, interstitial, or other cell types within the kidney. Thus the vascular and tubular actions of ANG II can be regulated by cell-to-cell (paracrine or autocrine) mediators produced in response to ANG II, thereby dampening or amplifying the primary effects. The most frequent integrated response to ANG II is net vasoconstriction, and the best known counteracting vasodilator mechanisms include NO and the vasodilator products of arachidonic acid metabolism, especially prostaglandin E 2 (PGE 2 ) and prostaglandin I 2 (PGI 2 ). ANG II acts directly at vascular smooth muscle cells to increase cytosolic calcium and stimulate phospholipase A 2 (PLA 2 ), which activates the formation of arachidonic acid. In this manner, it is possible for ANG II to induce renal vasodilation. ANG II increases renal NO production, which protects regional and total blood flow. 58 Most of the vasodilator action of NO is through cGMP, but NO may exert some of its vasodilator action in the absence of cGMP. 59 There is evidence that NO modulates the vasoconstrictor action of ANG II in the afferent but not the efferent arteriole. 60 Thus there is convincing evidence that ANG II stimulates NO, which buffers the vasoconstrictor actions of ANG II.
The AT 2 receptor recently has been shown to play an important role in ANG II stimulation of a number of renal vasodilator substances, including bradykinin (BK) and NO. This work was made possible by the introduction of a renal microdialysis technique that could measure small quantities of substances in renal interstitial fluid in vivo in conscious animals. 61 In 1996, it was first demonstrated that the AT 2 receptor antagonist PD blocked the increase in cGMP engendered by either dietary sodium restriction or exogenous ANG II administration during normal sodium intake. 61 Neither of these responses were affected by the AT 1 receptor antagonist losartan. 61 These observations suggested that the renal AT 2 receptor is stimulated to release cGMP in response to the physiological stimulus of sodium depletion. Since these renal responses are not present during normal sodium intake unless exogenous ANG II is given, the major physiological action of ANG II at the renal AT 2 receptor appears to depend on activation of the endogenous renin-angiotensin system. However, the immediate increase in renal cGMP in response to ANG II in sodium-replete animals, which can be blocked completely by PD, strongly suggests that AT 2 receptors are already present in the kidney and do not need to be induced or reexpressed to exert a physiological action. 61 AT 2 receptor-induced renal cGMP production is mediated by NO, as both the AT 2 receptor antagonist PD and the NO synthase (NOS) inhibitor L-NAME blocked the increase in renal cGMP elicited by sodium restriction or exogenous ANG II. 62 Since there was no additive inhibition of cGMP when PD and L-NAME were combined, the increase in renal NO is mediated by the AT 2 receptor. The NOS enzyme(s) responsible for AT 2 receptor stimulation of NO production appear to be multiple, including the neuronal NOS isoform. 62 Because BK is also a renal autacoid that stimulates NO production 63 through the B 2 receptor, 64 it was possible that the AT 2 receptor stimulates a renal BK-NO-cGMP vasodilator cascade. In 1996, it was discovered that the renin-angiotensin system stimulates renal BK production and cGMP formation through the AT 2 receptor. 65 Inhibition of renin but not AT 1 receptor blockade decreased markedly the elevated renal BK levels measured during sodium depletion. 65 This study initiated the concept that the AT 2 receptor releases BK and NO. In 1999, the ability of ANG II to stimulate BK production was confirmed. 66 Exogenous ANG II increased renal BK in conscious rats, and this response was abrogated completely by PD but was not influenced by losartan. 66 Neither PD nor losartan affected BK in the absence of exogenous ANG II, which suggests that activation of the renin-angiotensin system is once again required. 66 The evidence cited above formed the basis for a vasodilator/natriuretic cascade ( Figure 3 ) wherein ANG II activates the AT 2 receptor, resulting in the increased production of BK and NO. Alternatively, AT 2 receptor stimulation could increase BK, which alone could be responsible for increasing NO and cGMP. These results have been confirmed by studies in stroke-prone spontaneously hypertensive rats, in which AT 2 receptor stimulation increased aortic cGMP by increasing BK and NO formation. 67 Studies in genetically engineered mice lacking the AT 2 receptor (AT 2 -Null) have now confirmed the concept that the AT 2 receptor mediates a BK-NO-cGMP vasodilator cascade. 68 These animals are essentially normotensive under basal conditions 69, 70 but have profound and sustained pressor and antidiuretic/antinatriuretic hypersensitivity to ANG II. AT 2 -Null mice were found to have very low basal renal levels of BK and cGMP. 68 In response to dietary sodium restriction or exogenous ANG II for 1 week, AT 2 -Null failed to increase either BK or cGMP, which increased severalfold in wild-type mice (WT). Taken altogether, the evidence confirms the concept that the AT 2 receptor physiologically mediates the renal production of BK and NO. These studies further suggest that the absence of the AT 2 receptor and its vasodilator/natriuretic cascade is responsible for the markedly increased sensitivity of blood pressure and sodium excretion to ANG II in AT 2 -Null mice.
In addition to the above-mentioned mechanisms, there is evidence that an AT 2 receptor located in the apical membrane of renal proximal tubule cells is linked to PLA 2 , whereby arachidonic acid is released and metabolized by cytochrome P450 epoxygenase. 71 Recent in vitro studies demonstrate that the proximal tubule AT 2 receptor is linked to inhibition of sodium and bicarbonate absorption, an effect that opposes AT 1 receptor-mediated absorption. 72 These studies are quite consistent with the demonstrated natriuretic role of AT 2 receptors in vivo. 68 Several studies have suggested a role for AT 2 receptors in renal eicosanoid production and metabolism. The major renal vasodilator prostanoid is prostaglandin E 2 (PGE 2 ) and its formation occurs in response to ANG II as a result of PLA 2 release of substrate arachidonic acid. 73 PGE 2 is formed within the kidney as a result of ANG II stimulation of the AT 1 receptor. 61 The possibility that the AT 2 receptor might be involved in renal prostaglandin metabolism was introduced when it was shown that AT 2 receptor blockade in rats on a low sodium diet increased renal PGE 2 . 61 This increase in PGE 2 could be related to an effect of the AT 2 receptor on PGE 2 metabolism. Prostaglandin F 2␣ (PGF 2␣ ) can be formed directly from PGE 2 by PGE 2 9-ketoreductase or directly from the precursor prostanoid, PGH 2 . It was found that the AT 2 receptor increases PGF 2␣ formation, probably by stimulating conversion from PGE 2 , since the ratio of PGF 2␣ to PGE 2 , a measure of such conversion, is markedly decreased with AT 2 receptor blockade. 74 This interpretation is consistent with the demonstrated upregulation of PGE 2 9-ketoreductase by sodium depletion. 75 Nonetheless, it remains possible that the AT 2 receptor selectively limits the production of PGF 2␣ but not PGE 2 from PGH 2 .
In accord with the above observations, AT 2 -Null mice have increased renal PGE 2 and PGI 2 and decreased PGF 2 both basally and in response to sodium depletion or exogenous ANG II. 76 The renal vasodilator prostanoids, PGE 2 and PGI 2 , were both stimulated by AT 1 receptors, providing counterregulatory vasodilation in opposition to the AT 1 receptormediated vasoconstrictor action of ANG II. In addition, very high renal cAMP levels in AT 2 -Null compared with WT were normalized by blockade of the AT 1 receptor, which reduced PGE 2 and PGI 2 to low levels. 76 This raises the likelihood that these vasodilator prostanoids act physiologically through stimulation of adenylyl cyclase and cAMP production. Figure  3 summarizes the effects of AT 1 and AT 2 receptors on renal prostaglandin production and metabolism.
There also is evidence that the AT 2 receptor mediates vasodilation in the rabbit afferent arteriole through a cytochrome P-450 pathway, possibly by means of epoxyeicosatetraenoic acid. 77 Activation of the AT 2 receptor modulates AT 1 receptor-mediated vasoconstriction in the afferent arteriole of the spontaneously hypertensive rat. 78 The vasodilator action of ANG II stimulation of the AT 2 receptor in these direct vascular studies confirms the results of the studies in vivo.
The net effect of ANG II on renal function is a combination of AT 1 and AT 2 receptor-mediated events with the AT 1 receptor-mediated effects generally predominant. Thus ANG II administration results in net renal vasoconstriction and reduced glomerular filtration. These effects are modulated, however, by AT 2 receptor-stimulated BK, NO, and cGMP. The net sodium excretory response to ANG II depends on its concentration: Low concentrations inhibit sodium excretion, whereas higher concentrations induce natriuresis. At this time, we are still unsure which receptor mediates the natriuretic response to high concentrations of ANG II.
Role of the AT 2 Receptor in Control of Blood Pressure
As discussed earlier, AT 2 -Null mice have slightly elevated blood pressures compared with WT, but still well within the normotensive range. 68 -70,74 Stimulation with exogenous ANG II, either acutely or chronically, increases blood pressure to a much greater extent in AT 2 -Null than WT. AT 2 -Null infused with a low dose of ANG II (4 pmol/kg per minute) that does not affect blood pressure in WT increases blood pressure substantially into the hypertensive range in AT 2 -Null. 68 This increase in blood pressure response to ANG II in the absence of the AT 2 receptor is accompanied by deficiency of the BK-NO-cGMP vasodilator cascade, the absence of which causes the ANG II hypersensitivity. A possible additional reason for the ANG II hypersensitivity may be upregulation of AT 1 receptors triggered by AT 2 receptor deficiency. 79, 80 However, AT 1 receptor upregulation would not account for the deficiency of vasodilator autacoids in this model. The elevation of PGE 2 and PGI 2 in AT 2 -Null suggested the possibility that these vasodilator prostanoids might prevent hypertension in this model. Reduction of PGE 2 and PGI 2 with indomethacin, a cyclooxygenase inhibitor, resulted in a progressive and sustained increase in blood pressure well into the hypertensive range in AT 2 -Null while having no effect on blood pressure in WT. 76 Therefore, in AT 2 -Null, increased vasodilator prostanoids prevent hypertension that otherwise would accompany the hypersensitivity of blood pressure and sodium excretion to ANG II. This is an unusual example of the vasodilatory capacity of prostanoids in physiology.
The BK-NO-cGMP vasodilator cascade mediated by the AT 2 receptor suggested the possibility that the AT 2 receptor may subserve a protective role in blood pressure regulation. In a 2-kidney, 1-wrap model of renal vascular hypertension, activation of the renin-angiotensin system increases blood pressure through the AT 1 receptor. Blood pressure reduction with AT 1 receptor blockade with losartan was prevented by AT 2 receptor blockade with PD and by use of the BK-B 2 receptor antagonist icatibant. 66 Similar data are available for 2-kidney, 1-clip Goldblatt hypertensive animals (Carey, unpublished observations). Thus the AT 2 receptor engenders counterregulatory vasodilation and protects against a further increase in blood pressure in these models of angiotensindependent hypertension. Abrogation of the hypotensive action of AT 1 receptor blockade with AT 2 receptor inhibition suggests that at least some of the beneficial effects of AT 1 receptor blockade are mediated by the AT 2 receptor, possibly by the BK-NO-cGMP vasodilator cascade.
In the 2-kidney, 1-wrap model of angiotensin-dependent hypertension, the vasodilator autacoids BK, NO, and cGMP were markedly decreased in the ischemic kidney and augmented in the contralateral kidney. 66 The increase in vasodilator autacoids in the contralateral kidney was due to AT 2 receptor stimulation, since these were inhibited to control levels with PD. 66 In the ischemic kidney, the AT 1A receptor protein was downregulated in both kidneys, whereas the AT 2 receptor was downregulated only in the ischemic kidney. 44 Therefore the protective effect of the AT 2 receptor is probably mediated by augmentation of a BK-NO-cGMP vasodilator cascade in the contralateral, nonischemic kidney, in which AT 2 receptor expression is maintained.
In parallel with studies of angiotensin-dependent hypertension, investigators have demonstrated a role for the AT 2 receptor in the regulation of blood pressure in normal salt-restricted rats. 81, 82 In salt-restricted rats, AT 2 receptor blockade with PD was found to offset the blood pressurelowering effect of losartan or valsartan, which suggests that AT 1 receptor blockade lowers blood pressure, at least in part, by stimulation of AT 2 receptors caused by increased ANG II. 81, 82 AT 1 receptor blockade in these animals was associated with an increase in renal BK, NO, and cGMP. 82 AT 2 receptor blockade with PD inhibited both the hypotension and the renal responses of BK, NO, and cGMP to valsartan, confirming that during AT 1 receptor blockade there is concomitant stimulation of the AT 2 receptor. Furthermore, the increase in renal NO and cGMP during AT 1 receptor blockade appears to be mediated by BK because BK-B 2 receptor blockade inhibited this response (H.M.S., M. deGasparo, and R.M.C., unpublished data, 1999).
The discovery that the AT 2 receptor mediates a BK-NOcGMP vasodilator cascade 61, 62, [65] [66] [67] [68] has recently been confirmed in mice overexpressing the AT 2 receptor selectively in vascular smooth muscle cells. 82 In this study, AT 2 receptor expression was increased from low levels (7.5%) to Ϸ39% of the expression of the AT 1 receptor. 82 Animals with AT 2 receptor overexpression were normotensive. However, pressor responses in vivo and vasoconstriction in vitro to ANG II were absent in animals overexpressing the AT 2 receptor. In animals overexpressing the AT 2 receptor, vasoconstrictor responses to ANG II were restored with AT 2 receptor blockade and also with BK-B 2 receptor blockade or with NOS inhibition. The initiating event was proposed as AT 2 receptor activation of kininogenase through cellular acidification to induce BK production, 82 but the early part of the pathway requires further study. This study 82 is consistent with a protective role of the AT 2 receptor in blood pressure regulation and confirms the earlier discovered vasodilator paracrine mechanism of AT 2 receptor action via BK, NO, and cGMP.
The role of the AT 2 receptor in pressure-natriuresis has been controversial. Several studies from Sassard's group have indicated that pressure-natriuresis is inhibited by the AT 2 receptor. 83, 84 The majority of reports, however, indicate that the AT 2 receptor stimulates pressure-natriuresis. 66, 68, 85 In rats with 2-kidney, 1-wrap renovascular hypertension, pressurenatriuresis in the nonischemic kidney is accompanied by maintenance of AT 2 receptor expression and an increase in AT 2 receptor-dependent BK, NO, and cGMP. 66 In AT 2 -Null mice, an increase in pressure with ANG II is accompanied by a sustained antinatriuresis. 68 Also, AT 2 -Null mice have their pressure-natriuresis curves shifted rightward in association with reduced renal cortical and medullary blood flow. 85 Resolution of these differences is important because virtually all hypertensive processes are accompanied by a reduction in pressure-natriuresis resulting in renal sodium retention. 86 Figure 4 summarizes the role of AT 1 and AT 2 receptors in blood pressure regulation.
Opposing Actions of AT 1 and AT 2 Receptors
As is true for other peptide receptor families, the interaction between receptor subtypes within a family may be important to the physiological response to the agonist. In general, ANG II effects at the AT 1 receptor are opposed by actions at the AT 2 receptor. This principle applies to neuronal effects, actions on cell proliferation and differentiation, angiogenesis, and chronotropic effects in the heart. 30, [87] [88] [89] [90] [91] In the skin, ANG II binding to AT 1 receptors increases inositol phosphate production, whereas ANG II inhibits inositol phosphate production by the AT 2 receptor. 92 In the gastrointestinal tract, AT 1 receptors oppose AT 2 receptors in sodium and water absorption, and there is clear physiological opposition between these receptors as sodium transport is finely tuned. 54 In the kidney, the AT 1 receptor induces vasoconstriction and sodium retention, whereas the AT 2 receptor promotes vasodilation and natriuresis. 66, 68, 72 AT 2 receptor blockade prevents the hypotensive effects of AT 1 receptor blockade and the AT 2 receptor mediates the depressor response to ANG II. 66, 79, 80 In general, the AT 1 receptor stimulates protein phosphorylation and the AT 2 receptor stimulates protein dephosphorylation, which counterbalances the effects of protein kinases, especially MAP kinase, stimulated by the AT 1 receptor. Figure 5 indicates the role of AT 2 receptors in counterbalancing the actions of AT 1 receptors. 
Conclusions
The past 5 years have witnessed a dramatic change in the way we view the renin-angiotensin system. Until recently, the vascular and renal actions of ANG II were thought to be transduced solely through the AT 1 receptor, and the function of the AT 2 receptor was unknown. However, recent information has emerged in support of a role for the AT 2 receptor in the regulation of blood pressure and kidney function. The AT 2 receptor mediates a vasodilator/natriuretic renal autacoid cascade that includes BK, NO, and cGMP. This pathway is important as a counterregulatory mechanism opposing the vasoconstrictor/antinatriuretic actions of ANG through the AT 1 receptor and plays a protective role in renal vascular hypertension. The AT 2 receptor also modulates renal prostaglandins, which play an important role in blood pressure regulation. Further studies in AT 1 and AT 2 receptor-deficient animals will help clarify these mechanisms. From the actions described for the AT 2 receptor thus far, one would logically predict that a specific AT 2 receptor agonist may have beneficial and protective advantages in the treatment of hypertension and renal and cardiovascular disease.
